Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GHTF Pilot Update: Japan Joins In, US/Canada To Coordinate Parallel Reviews

This article was originally published in The Gray Sheet

Executive Summary

FDA's existing joint review program with Canada could be a vehicle for the agency to conduct parallel reviews of cardiovascular devices using the Global Harmonization Task Force's common premarket submission format

You may also be interested in...



FDA Stresses Early Discussion Of Foreign Data In Post-MDUFMA World

CDRH is urging sponsors to schedule pre-filing meetings with the device center, especially if firms plan to use data collected in trials conducted outside the U.S

FDA Stresses Early Discussion Of Foreign Data In Post-MDUFMA World

CDRH is urging sponsors to schedule pre-filing meetings with the device center, especially if firms plan to use data collected in trials conducted outside the U.S

CDRH Hits Deficit Spending Realities In Planning For FY 2004 Budget Cycle

Device industry members need to help prioritize which parts of CDRH are indispensable in a year of an anticipated funding shortfall at the agency, Center for Devices & Radiological Health Director David Feigal counseled at a June 6 AdvaMed device submissions workshop in Rockville, Maryland

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel